Dow Jones

39 118,86

-0,12%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

NKTX

Nkarta (NKTX)

Nkarta Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:NKTX

1 2 3 4 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
27/06/2024	12h00	GlobeNewswire Inc.	Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications	NASDAQ:NKTX	Nkarta Inc
14/06/2024	22h10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTX	Nkarta Inc
14/06/2024	22h04	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:NKTX	Nkarta Inc
13/06/2024	22h22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTX	Nkarta Inc
13/06/2024	22h01	GlobeNewswire Inc.	Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors	NASDAQ:NKTX	Nkarta Inc
09/05/2024	22h14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NKTX	Nkarta Inc
09/05/2024	22h01	GlobeNewswire Inc.	Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights	NASDAQ:NKTX	Nkarta Inc
03/04/2024	22h02	GlobeNewswire Inc.	Nkarta to Participate in Upcoming Investor Conferences	NASDAQ:NKTX	Nkarta Inc
25/03/2024	11h30	GlobeNewswire Inc.	Nkarta Announces Pricing of $240 Million Underwritten Offering	NASDAQ:NKTX	Nkarta Inc
21/03/2024	21h01	GlobeNewswire Inc.	Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	NASDAQ:NKTX	Nkarta Inc
01/03/2024	22h32	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTX	Nkarta Inc
09/02/2024	12h38	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:NKTX	Nkarta Inc
03/01/2024	22h15	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:NKTX	Nkarta Inc
10/12/2023	02h31	GlobeNewswire Inc.	Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition	NASDAQ:NKTX	Nkarta Inc
13/11/2023	14h25	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NKTX	Nkarta Inc
09/11/2023	22h02	GlobeNewswire Inc.	Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights	NASDAQ:NKTX	Nkarta Inc
07/11/2023	14h02	GlobeNewswire Inc.	Nkarta to Participate at Upcoming Investor Conferences	NASDAQ:NKTX	Nkarta Inc
27/10/2023	22h05	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:NKTX	Nkarta Inc
17/10/2023	18h00	Dow Jones News	Nkarta's Stock Climbs 28% After FDA Approves Drug Application	NASDAQ:NKTX	Nkarta Inc
17/10/2023	17h47	PR Newswire (US)	Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis	NASDAQ:NKTX	Nkarta Inc
17/10/2023	13h01	GlobeNewswire Inc.	Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis	NASDAQ:NKTX	Nkarta Inc
16/10/2023	22h01	GlobeNewswire Inc.	Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures	NASDAQ:NKTX	Nkarta Inc
10/08/2023	13h01	GlobeNewswire Inc.	Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights	NASDAQ:NKTX	Nkarta Inc
03/08/2023	14h02	GlobeNewswire Inc.	Nkarta to Participate at Upcoming Investor Conference	NASDAQ:NKTX	Nkarta Inc
05/07/2023	22h02	GlobeNewswire Inc.	Nkarta Appoints Alyssa Levin Chief Financial and Business Officer	NASDAQ:NKTX	Nkarta Inc
27/06/2023	13h08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:NKTX	Nkarta Inc
27/06/2023	13h01	GlobeNewswire Inc.	Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia	NASDAQ:NKTX	Nkarta Inc
26/06/2023	22h01	GlobeNewswire Inc.	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program	NASDAQ:NKTX	Nkarta Inc
22/06/2023	22h26	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:NKTX	Nkarta Inc
10/06/2023	16h47	GlobeNewswire Inc.	Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma	NASDAQ:NKTX	Nkarta Inc